

# 2019 AUA BPH Guideline Update:

## Rezūm™ Water Vapor Therapy and GreenLight™ Laser Therapy

The **Rezūm System** was added to the benign prostatic hyperplasia (BPH) guideline with a role for patients looking to preserve sexual function, and for physicians looking for flexibility to treat all areas of enlarged prostate in the office or ambulatory surgery center (ASC).

**Guideline statement:** Water vapor thermal therapy may be offered to eligible patients who desire preservation of erectile and ejaculatory function.<sup>1</sup>

### The Rezūm System was recommended as an option in patients with a desire to preserve sexual function:

"Long-term, no de novo ED was reported, and no significant changes in IIEF-EF scores or ejaculatory functions scores."<sup>1</sup>

### The Rezūm System may be offered to patients with median lobes:

"Unlike other MISTs, this technology did not exclude those men with obstructing middle lobes or median bars."<sup>1</sup>

The **GreenLight Laser** was recommended as a versatile treatment for BPH with the same evidence and recommendation level as transurethral resection of the prostate (TURP).

**Guideline statement:** Clinicians should consider photoselective vaporization of the prostate (PVP) as an option using 120W or 180W platforms for patients for the treatment of lower urinary tract symptoms (LUTS) attributed to BPH.<sup>1</sup>

**The GreenLight Laser is also recommended in high-risk patients:**  
"Multiple studies have found that PVP is safe and effective for patients who continue their anticoagulant/antiplatelet therapy, with negligible transfusion rates."<sup>1</sup>

**The GreenLight Laser shows equivalent outcomes to TURP:**  
"...similar outcomes with regards to symptomatic, urinary improvement in LUTS/BPH and complication rates between TURP and PVP."<sup>1</sup>



Boston Scientific offers solutions to treat a wide variety of BPH patient and prostate types, and the revised BPH guideline supports the following evidence-based recommendations.<sup>1</sup>

	<b>Rezūm™</b>	<b>GreenLight™</b>
Prostate Size	Up to 80g	✓
Median Lobe	✓	✓
Sexual Function	✓	
Retention		✓
Medically Complicated		✓

To learn more about the Boston Scientific portfolio of complementary BPH technology and other urology solutions, contact your local sales representative or visit [www.bostonscientific.eu](http://www.bostonscientific.eu)

1. Foster HE, Barry MJ, Dahm P, et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline. *J Urol.* 2018 Jun 11. [Epub ahead of print]

The Rezūm™ System is intended to relieve symptoms, obstructions, and reduce prostate tissue associated with BPH. It is indicated for men ≥ 50 years of age with a prostate volume  $30\text{cm}^3 \leq 80\text{cm}^3$ . The Rezūm System is also indicated for treatment of prostate with hyperplasia of the central zone and/or a median lobe.

The GreenLight™ Laser System is intended for incision/excision, vaporization, ablation, hemostasis and coagulation of soft tissue, including photoselective vaporization of the prostate for benign prostatic hyperplasia (BPH). The laser system is contraindicated for patients who: are contraindicated for surgery, contraindicated where appropriate anaesthesia is contraindicated by patient history, have calcified tissue, require hemostasis in >2mm vessels, have uncontrolled bleeding disorders, have prostate cancer, have acute urinary tract infection (UTI) or severe urethral stricture. Possible risks and complications include, but are not limited to, irritative symptoms (dysuria, urgency, frequency), retrograde ejaculation, urinary incontinence, erectile dysfunction, hematuria - gross, UTI, bladder neck contracture/outlet obstruct, urinary retention, perforation - prostate, urethral stricture. URO-545402-AA

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labelling supplied with each device. Information for use only in countries with applicable health authority registrations. This material not intended for use in France.

All trademarks are the property of their respective owners.

URO-647403-AA Printed in Germany by medicalvision.

**Boston  
Scientific**  
Advancing science for life™

[www.bostonscientific.eu](http://www.bostonscientific.eu)

© 2019 Boston Scientific Corporation or its affiliates. All rights reserved.  
DINURO2411EA